Summary statistics (mean (
Toxicant . | CASRN . | CSF set II (mg/kg-d)−1 . | R . | . | Lt . | . | Ult . | . | PREP . | . | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | \(\overline{\mathrm{ILCR}}_{1}^{\mathit{i}}\)
. | SD . | \(\overline{\mathrm{ILCR}}_{1}^{\mathit{i}}\)
. | SD . | \(\overline{\mathrm{ILCR}}_{1}^{\mathit{i}}\)
. | SD . | \(\overline{\mathrm{ILCR}}_{1}^{\mathit{i}}\)
. | SD . | ||||||||||
Acetaldehyde | 75-07-0 | 0.01* | 7e−05 | 8e−06 | 7e−05 | 8e−06 | 4e−05 | 1e−05 | 5e−06 | 5e−06 | ||||||||||
Acrylonitrile | 107-13-1 | 1.0* | 1e−04 | 3e−05 | 1e−04 | 3e−05 | 6e−05 | 3e−05 | 1e−05 | 1e−05 | ||||||||||
4-Aminobiphenyl | 92-67-1 | 21* | 5e−07 | 9e−08 | 4e−07 | 4e−08 | 2e−07 | 6e−08 | 2e−07 | 9e−08 | ||||||||||
Arsenic | 7440-38-2 | 12* | 8e−07 | 2e−07 | 6e−07 | 2e−07 | 3e−07 | 2e−07 | 2e−08 | NA† | ||||||||||
Benzene | 71-43-2 | 0.1* | 4e−05 | 5e−06 | 3e−05 | 4e−06 | 2e−05 | 8e−06 | 4e−06 | 4e−06 | ||||||||||
Benzo[a]pyrene | 50-32-8 | 3.9* | 5e−07 | 8e−08 | 4e−07 | 5e−08 | 2e−07 | 6e−08 | 4e−08 | 5e−08 | ||||||||||
1,3-Butadiene | 106-99-0 | 0.6* | 2e−04 | 4e−05 | 2e−04 | 4e−05 | 1e−04 | 4e−05 | 3e−05 | 3e−05 | ||||||||||
Cadmium | 7440-43-9 | 15* | 1e−05 | 2e−06 | 8e−06 | 1e−06 | 4e−06 | 2e−06 | 6e−07 | 5e−07 | ||||||||||
Formaldehyde | 50-00-0 | 0.021* | 7e−06 | 1e−06 | 5e−06 | 2e−06 | 2e−06 | 1e−06 | 1e−06 | 1e−06 | ||||||||||
Lead | 7439-92-1 | 0.042* | 1e−08 | 2e−09 | 1e−08 | 2e−09 | 5e−09 | 2e−09 | 3e−09 | 1e−10 | ||||||||||
NNK‡ | 64091-91-4 | 49§ | 4e−05 | 5e−06 | 3e−05 | 5e−06 | 2e−05 | 6e−06 | 4e−06 | 7e−07 | ||||||||||
N-Nitrosonornicotine | 80508-23-2 | 1.4* | 2e−06 | 3e−07 | 1e−06 | 3e−07 | 8e−07 | 3e−07 | 1e−07 | 6e−08 | ||||||||||
Quinoline‡ | 91-22-5 | 3∥ | 2e−05 | 8e−06 | 1e−05 | 4e−06 | 7e−06 | 2e−06 | 2e−06 | 1e−06 | ||||||||||
Cancer risk subtotals | ||||||||||||||||||||
Human lung carcinogens∥,¶ \(\overline{\mathrm{ILCR}}_{1}^{\mathrm{sub{\Sigma}}\mathrm{{-}lung}}\) | 1e−04 | 3e−05 | 1e−04 | 3e−05 | 7e−05 | 3e−05 | 1e−05 | 1e−05 | ||||||||||||
All cancers: \(\overline{\mathrm{ILCR}}_{1}^{\mathrm{sub}\mathrm{{\Sigma}}}\) | 5e−04 | 7e−05 | 5e−04 | 8e−05 | 3e−04 | 9e−05 | 4e−05 | 5e−05 |
Toxicant . | CASRN . | CSF set II (mg/kg-d)−1 . | R . | . | Lt . | . | Ult . | . | PREP . | . | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | \(\overline{\mathrm{ILCR}}_{1}^{\mathit{i}}\)
. | SD . | \(\overline{\mathrm{ILCR}}_{1}^{\mathit{i}}\)
. | SD . | \(\overline{\mathrm{ILCR}}_{1}^{\mathit{i}}\)
. | SD . | \(\overline{\mathrm{ILCR}}_{1}^{\mathit{i}}\)
. | SD . | ||||||||||
Acetaldehyde | 75-07-0 | 0.01* | 7e−05 | 8e−06 | 7e−05 | 8e−06 | 4e−05 | 1e−05 | 5e−06 | 5e−06 | ||||||||||
Acrylonitrile | 107-13-1 | 1.0* | 1e−04 | 3e−05 | 1e−04 | 3e−05 | 6e−05 | 3e−05 | 1e−05 | 1e−05 | ||||||||||
4-Aminobiphenyl | 92-67-1 | 21* | 5e−07 | 9e−08 | 4e−07 | 4e−08 | 2e−07 | 6e−08 | 2e−07 | 9e−08 | ||||||||||
Arsenic | 7440-38-2 | 12* | 8e−07 | 2e−07 | 6e−07 | 2e−07 | 3e−07 | 2e−07 | 2e−08 | NA† | ||||||||||
Benzene | 71-43-2 | 0.1* | 4e−05 | 5e−06 | 3e−05 | 4e−06 | 2e−05 | 8e−06 | 4e−06 | 4e−06 | ||||||||||
Benzo[a]pyrene | 50-32-8 | 3.9* | 5e−07 | 8e−08 | 4e−07 | 5e−08 | 2e−07 | 6e−08 | 4e−08 | 5e−08 | ||||||||||
1,3-Butadiene | 106-99-0 | 0.6* | 2e−04 | 4e−05 | 2e−04 | 4e−05 | 1e−04 | 4e−05 | 3e−05 | 3e−05 | ||||||||||
Cadmium | 7440-43-9 | 15* | 1e−05 | 2e−06 | 8e−06 | 1e−06 | 4e−06 | 2e−06 | 6e−07 | 5e−07 | ||||||||||
Formaldehyde | 50-00-0 | 0.021* | 7e−06 | 1e−06 | 5e−06 | 2e−06 | 2e−06 | 1e−06 | 1e−06 | 1e−06 | ||||||||||
Lead | 7439-92-1 | 0.042* | 1e−08 | 2e−09 | 1e−08 | 2e−09 | 5e−09 | 2e−09 | 3e−09 | 1e−10 | ||||||||||
NNK‡ | 64091-91-4 | 49§ | 4e−05 | 5e−06 | 3e−05 | 5e−06 | 2e−05 | 6e−06 | 4e−06 | 7e−07 | ||||||||||
N-Nitrosonornicotine | 80508-23-2 | 1.4* | 2e−06 | 3e−07 | 1e−06 | 3e−07 | 8e−07 | 3e−07 | 1e−07 | 6e−08 | ||||||||||
Quinoline‡ | 91-22-5 | 3∥ | 2e−05 | 8e−06 | 1e−05 | 4e−06 | 7e−06 | 2e−06 | 2e−06 | 1e−06 | ||||||||||
Cancer risk subtotals | ||||||||||||||||||||
Human lung carcinogens∥,¶ \(\overline{\mathrm{ILCR}}_{1}^{\mathrm{sub{\Sigma}}\mathrm{{-}lung}}\) | 1e−04 | 3e−05 | 1e−04 | 3e−05 | 7e−05 | 3e−05 | 1e−05 | 1e−05 | ||||||||||||
All cancers: \(\overline{\mathrm{ILCR}}_{1}^{\mathrm{sub}\mathrm{{\Sigma}}}\) | 5e−04 | 7e−05 | 5e−04 | 8e−05 | 3e−04 | 9e−05 | 4e−05 | 5e−05 |
NOTE: Conventional cigarettes classified by FTC tar yield as follows (30): regular, tar ≥ 15.0 mg; light, 6.0 mg ≤ tar < 15.0 mg; and ultralight, 1.0 ≤ tar < 6.0 mg. PREP cigarettes not characterized by tar content.
Office of Environmental Health Hazard Assessment, California Environmental Protection Agency. Sept. 2004 Cancer Potency List (46).
NA = not available: limited PREP yield data did not allow calculations for some chemicals. Each mean corresponds to a different number of PREPs because each PREP study measured different chemicals.
CSF was determined from an oral exposure study.
CSF, 49 for all cancer end points. California Environmental Protection Agency. Sept. 2001 Expedited Cancer Potency Values and No Significant Risk Levels for Six Proposition 65 Carcinogens (47).
Integrated Risk Information System, U.S. Environmental Protection Agency (44).